Verrica Pharmaceuticals reported total revenue of $35.6 million for the full year 2025, a 368% increase from $7.6 million in 2024. Net revenue from its FDA‑approved molluscum treatment YCANTH reached $15.3 million, driven by a 99% jump in applicator units dispensed to 51,296 units in 2025 versus 25,773 in 2024. The revenue beat was largely fueled by strong domestic demand and milestone payments from the partnership with Torii Pharmaceutical, which launched YCANTH in Japan during the year.
The company posted a GAAP net loss per share of $-0.57 for Q4 2025, missing the consensus estimate of $-0.43 by $0.14. The EPS miss reflects higher operating costs relative to revenue growth and a slight sequential decline in YCANTH unit sales from Q3 to Q4, which tempered the earnings impact despite the overall revenue upside.
YCANTH dispensed units rose to 51,296 in 2025, a 99% year‑over‑year increase, but the company noted a sequential drop from the previous quarter. Management attributed the dip to commercial execution factors, suggesting that while overall demand remains strong, there are short‑term headwinds that could affect quarterly momentum.
Operating expenses, including selling, general and administrative costs, fell more than 40% from the prior year, underscoring disciplined cost management. Gross product margins improved sharply, reaching 81.9% in Q4 2025 and 85.7% for the full year, up from negative margins in Q4 2024, indicating strong pricing power and efficient cost control.
Verrica has no outstanding debt and its cash runway extends into the first quarter of 2027, giving the company flexibility to invest in late‑stage pipeline programs for common warts and basal cell carcinoma while maintaining its commercial foothold in the United States.
Market reaction to the earnings was negative, driven primarily by the EPS miss and the sequential decline in YCANTH units. Investors weighed the revenue beat and margin expansion against the earnings shortfall and headwinds, leading to a cautious outlook for the company’s near‑term performance.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.